Federal Practitioner

All SpecialtiesPRESENTED BY MDedge

CME Events
REGISTER or LOGIN

/

Federal Practitioner

ADVERTISEMENT

SGLT2 inhibitors, GLP-1 RAs are effective, but costly in T2D

July 10, 2019|Federal Practitioner

Randy Dotinga;Katie Lennon

×

ADVERTISEMENT

ADVERTISEMENT

ADVERTISEMENT

This Publication

Advertise
Digital Edition/App
Contact Us
Corporate Management
Editorial Advisory Association
Editorial Policies
Multimedia
Submission Guidelines
Subscribe to Federal Practitioner

Facebook
Twitter

Top Sections

Best Practices
Government and Regulations
Original Research

Highlighted from this site and network

Digital Supplements

Editorial Policy

Medscape Customer Support

Frequently Asked Questions

Advertise with MDedge

See more with MDedge! See our Other Publications

Copyright © 2025 Frontline Medical Communications Inc., Newark, NJ, USA. All rights reserved. Unauthorized use prohibited. The information provided is for educational purposes only. Use of this Web site is subject to the medical disclaimer.